ARCHIVES OF DERMATOLOGICAL RESEARCH皮肤病学研究档案
ARCHIVES OF DERMATOLOGICAL RESEARCH(英文缩写 ARCH DERMATOL RES),ISSN 0340-3696,eISSN 1432-069X,中文译名:皮肤病学研究档案 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.033 | Q2 |
| 2022 | 3.000 | Q2 |
| 2023 | 1.800 | Q3 |
| 2024 | 2.100 | Q3 |
| 2025 | 2.500 | Q2 |
ARCHIVES OF DERMATOLOGICAL RESEARCH 最新收录文献
-
2. Diagnosis of immunobullous diseases in underrepresented groups: an all of us database study.
PMID:日期:2026-01-01该文献暂无摘要。
-
3. Vitiligo and Risk of Gastrointestinal Disorders in the United States: A Case-Control Study.
PMID:日期:2026-01-01该文献暂无摘要。
-
6. Mohs micrographic surgery is non-inferior to wide local excision for disease specific survival in sebaceous carcinoma: analysis of the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021).
6. 在皮脂腺癌的疾病特异性生存率方面，莫氏显微手术不亚于广泛的局部切除：监测、流行病学和最终结果（SEER）数据库分析（2000-2021）PMID:日期:2025-06-11该文献暂无摘要。
-
7. Nicotinamide for secondary keratinocyte carcinoma prevention in solid organ transplant recipients.
PMID:日期:2025-06-11Nicotinamide has many well-established chemopreventive properties in protecting against ultraviolet-induced skin damage, mitigating inflammation, and reducing keratinocyte carcinoma (KC) development among immunocompetent individuals. Its effectiveness in immunosuppressed patients, however, is unclear. There is conflicting research on whether nicotinamide effectively decreases KCs in immunosuppressed solid organ transplant recipients (SOTRs). This study assesses the effectiveness of nicotinamide in the secondary prevention of KC in immunosuppressed patients. We conducted a retrospective cohort study in a single tertiary care institution. The primary outcome was KC incidence in the year before and after nicotinamide supplementation. Secondary outcomes included the incidence of invasive squamous cell carcinoma (SCC), SCC in situ (SCCis), and basal cell carcinoma (BCC) over one- and two-year intervals. All included patients had taken oral nicotinamide, 500 milligrams twice daily, for at least one year. A total of 47 SOTRs (74.5% male; mean age 65.2 years) were included in our retrospective cohort study. Of 81 patients initially screened, 34 were excluded due to inadequate follow-up, dermatologic care outside our institution, or early discontinuation of nicotinamide. At one year post-nicotinamide supplementation, total KC incidence decreased from 224 (78 SCC, 103 SCCis, 43 BCC) to 121 cases (40 SCC, 55 SCCis, 26 BCC), a mean reduction of 2.19 KCs (95% CI: -3.48 to -0.90; p = 0.0012). Significant reductions were observed in SCC (mean decrease of 1.15; 95% CI: -1.78 to -0.52; p = 0.00081) and SCCis (mean decrease of 1.37; 95% CI: -2.61 to -0.13; p = 0.032). BCC reduction was not statistically significant (p = 0.13). In the 31 patients with two-year follow-up data, KC incidence declined from 234 to 167, a mean reduction of 2.18 KCs (95% CI: -4.18 to -0.14; p = 0.037). Sensitivity analyses excluding patients on concomitant acitretin confirmed that reductions in total KC incidence maintained significance at both one-year and two-year intervals. Nicotinamide supplementation significantly decreased KC incidence in immunosuppressed SOTRs over the one-year and two-year intervals. We recommend nicotinamide as a low-risk, low-cost chemopreventive supplement for reducing KCs in SOTRs.
-
8. Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review.
8. 标签外使用生物制剂和janus激酶（JAK）抑制剂治疗瘢痕性脱发：一项叙述性综述PMID:日期:2025-06-09Scarring alopecias, including lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans, central centrifugal cicatricial alopecia, discoid lupus erythematosus, and dissecting cellulitis cause permanent destruction of hair follicles, resulting in patches of hair loss that can be devastating for patients. Treatment options for scarring alopecias focus on disease stabilization and currently include corticosteroids and immunosuppressive agents, which often offer inconsistent disease improvements with waning patient satisfaction, especially in severe stages of the condition. Recent advances in therapeutics such as biologics and JAK inhibitors may offer some potential for disease stabilization and resolution through modulation of the inflammatory and immune-mediated pathways of scarring alopecias. This review examines literature reporting the off-label use of biologics and JAK inhibitors for the treatment of scarring alopecias. We find that TNF-α, IL-17, and JAK inhibitors demonstrate the most potential of currently available agents, with IL-23 and Interferon Alpha Receptor 1 inhibitors also showing some benefit.
-
9. Wells syndrome: emerging triggers and treatments- an updated systematic review.
PMID:日期:2025-06-09Wells syndrome (eosinophilic cellulitis) is a rare inflammatory dermatosis characterized by erythematous, edematous plaques and dermal eosinophilic infiltration. Understanding its evolving triggers and treatment options is critical for optimizing management, particularly in corticosteroid-refractory cases. To systematically review newly reported immunologic and iatrogenic triggers of Wells syndrome, as well as emerging therapies, with the goal of updating clinical guidance. This review focuses on diagnosis and therapy, emphasizing outcomes in patients with refractory or relapsing disease. A systematic literature search was conducted following PRISMA 2020 guidelines across six databases for English-language studies published between January 2016 and May 2025. Studies were eligible if they described new triggers or treatments for Wells syndrome. Article selection and data extraction were performed independently by two reviewers. Risk of bias was assessed using the Joanna Briggs Institute and Newcastle-Ottawa tools. Twenty-four studies met inclusion criteria: 21 case reports, 2 case series, and 1 retrospective cohort study. Newly identified triggers included COVID-19 infection, SARS-CoV-2 and influenza vaccines, aluminum- and gelatin-containing pediatric vaccines, and biologic therapies such as ustekinumab and tumor necrosis factor-alpha (TNF-α) inhibitors. In vaccine-related cases, causality was supported by positive patch testing. Novel therapies trialed in corticosteroid-refractory or relapsing patients included dupilumab, topical ruxolitinib, abrocitinib, and mepolizumab. Most patients experienced complete or near-complete resolution. However, recurrences were common, particularly in idiopathic cases or upon re-exposure to known triggers. Recent literature expands the clinical spectrum of Wells syndrome, highlighting new immunologic and iatrogenic triggers. Targeted treatments, especially biologics and Janus kinase inhibitors, demonstrate promising results and may offer steroid-sparing alternatives for patients with refractory disease. Clinicians should consider emerging triggers in differential diagnosis and evaluate newer therapies in recurrent or treatment-resistant cases. Further prospective and registry-based studies are warranted to validate efficacy and support development of evidence-based management guidelines.
-
10. Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database.
10. 基于FAERS数据库的Tapinarof相关不良事件的不成比例分析PMID:日期:2025-06-09Tapinarof, a novel topical aryl hydrocarbon receptor (AhR) modulator, has demonstrated promising therapeutic efficacy in the treatment of plaque psoriasis. However, its comprehensive safety profile in real-world settings remains underexplored. To assess the post-marketing safety of Tapinarof using data from the FDA Adverse Event Reporting System (FAERS), with a focus on identifying significant adverse event (AE) signals and subgroup-specific risks. A retrospective disproportionality analysis was conducted on FAERS data from Q2 2022 to Q4 2024. Reports listing Tapinarof as the primary suspect drug were extracted and analyzed using four established signal detection algorithms (ROR, PRR, EBGM, IC), complemented by Bonferroni correction for multiple comparisons. A total of 1,227 AE reports were included. The majority of reports originated from adults aged 18-64 years and were submitted by healthcare professionals, with a balanced male-to-female ratio. The most frequently observed AE signals were related to skin and subcutaneous tissue disorders, including keratosis pilaris, contact dermatitis, and application site acne. Notable signals were also detected for infections (e.g., pustules) and hypersensitivity reactions. A novel tumor-related signal was identified for keratoacanthoma, with statistically significant associations also observed for squamous cell carcinoma of the skin. Gender subgroup analysis revealed a higher incidence of dermatological AEs in females and slightly stronger neoplasm-related signals in males. Age, weight, and indication data were largely missing, limiting subgroup-specific interpretation. Tapinarof is generally well tolerated in adults, particularly for psoriasis treatment, but is associated with strong cutaneous and immune-related AE signals. Novel findings-including pharyngeal swelling and tumor-related events-warrant heightened clinical vigilance, especially in patients requiring long-term or large-area application. Gender differences in AE reporting further underscore the need for personalized risk management strategies. Further longitudinal and mechanistic studies are essential to confirm these associations and guide safer clinical use.